MedWatch

Danish Medicines Council rejects Johnson & Johnson's psoriasis medicine: "Worse than existing standard treatment"

Tremfya will not be becoming the standard treatment for psoriatic arthritis, a type of arthritis which can accompany the inflammatory skin disease.

Photo: BRENDAN MCDERMID/REUTERS / X90143

The Danish Medicines Council has refused to recommend Johnson & Johnson's drug Tremfya as the standard treatment for psioratic arthritis in Denmark - no matter how it is priced.

Psoriatic arthritis is a form of arthritis which affects 5-30 percent of patients with psoriasis and is characterized by inflamed joints.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs